A study presented at ESMO 2018 demonstrated that incidence of skin toxicity in patients with multiple myeloma undergoing lenalidomide therapy was lower in those who received prior bortezomib.
Assessment of a subgroup of a cohort study revealed that many patients undergoing tamoxifen therapy for early-stage breast cancer do not adhere to their prescribed treatment, even though they claim adherence on patient surveys.
An analysis of pooled data from 4 randomized controlled clinical trials revealed that male and female patients experience different chemotherapy side effects and at different severities, according to a poster presented at ESMO 2018 Congress.
Researchers surveyed 60 breast cancer survivors to determine if their desire to achieve pregnancy had changed after completing treatment. These findings were presented at ESMO 2018 Congress.
Study findings presented at ESMO 2018 Congress revealed the effect of a shorter, 9-week course of trastuzumab on disease-free survival (DFS) and cardiac toxicity in women with HER2-positive breast cancer.
